The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors
暂无分享,去创建一个
M. Pini | A. Busca | B. Bruno | R. Passera | R. Cavallo | C. Costa | E. Maffini | L. Giaccone | E. Audisio | F. Zallio | C. Dellacasa
[1] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[2] J. Cheong,et al. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia , 2015, Annals of Hematology.
[3] R. Cavallo,et al. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[4] B. Sarina,et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] S. Devlin,et al. Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] B. Sandmaier,et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. , 2013, Blood.
[7] H. Deeg,et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Fahle,et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML , 2013, Bone Marrow Transplantation.
[9] KyungMann Kim,et al. Contrasting treatment‐specific survival using double‐robust estimators , 2012 .
[10] R. Schlenk,et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.
[11] L. Lanier,et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. , 2012, Blood.
[12] S. Mackinnon,et al. CMV-specific cellular therapy for acute myeloid leukemia? , 2012, Blood.
[13] A. Barrett. CMV: when bad viruses turn good. , 2011, Blood.
[14] S. Schnittger,et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. , 2011, Blood.
[15] S. Grace,et al. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. , 2010, Blood.
[16] E. Thiel,et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion , 2010, International journal of hematology.
[17] M. Daperno,et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease , 2007, Inflammatory bowel diseases.
[18] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[20] N. Keiding,et al. GRAFT-VERSUS-LEUKAEMIA ACTIVITY ASSOCIATED WITH CYTOMEGALOVIRUS ANTIBODY POSITIVE BONE MARROW DONORS IN ACUTE MYELOID LEUKAEMIA , 1987, The Lancet.
[21] G. Gahrton,et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection , 1986, British journal of haematology.
[22] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.
[23] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[24] R. Vij,et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] D. Baarle,et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia , 2013, Leukemia.
[26] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] Marc Bonneville,et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. , 2005, Immunity.
[28] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .